Kristi Rosa

Elacestrant, an oral selective estrogen receptor degrader, will undergo evaluation by the FDA for patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.

Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.

The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.

Tisagenlecleucel received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab received FDA approval as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status

Ivosidenib plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring IDH1 mutations.

Azacitidine (Vidaza) is now FDA approved for pediatric patients with newly diagnosed myelomonocytic leukemia.

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer.

Fam-trastuzumab deruxtecan-nxki is now an FDA-approved regimen for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

The FDA has granted a priority review designation to darolutamide plus docetaxel for patients with metastatic hormone-sensitive prostate cancer.

The phase 3 RATIONALE 309 trial highlighted the combined efficacy of tislelizumab and chemotherapy in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.

An update from the phase 3 SKYSCRAPER-02 trial found that tiragolumab to atezolizumab did not significantly improve progression-free survival in extensive-stage small cell lung cancer.

Patients with metastatic RET fusion–positive non–small cell lung cancer experienced encouraging responses with selpercatinib.

Axicabtagene ciloleucel is now FDA-approved for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

The addition of temozolomide to a low-dose treatment plan of ipilimumab and nivolumab extended progression-free survival among patients with metastatic colorectal cancer.

New data support the use of ribociclib plus letrozole in the treatment of patients with postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.

Frontline treatment with poziotinib yielded promising overall response rates in patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.

The FDA has granted a priority review designation of ivosidenib plus azacitidine on the indication of previously untreated IDH1-mutated acute myeloid leukemia.

Adagrasib is currently being considered for approval as a treatment option for previously treated patients with KRAS G12C-mutated non-small cell lung cancer.

Frontline treatment with brentuximab vedotin and chemotherapy yielded superior survival outcomes in patients with advanced classical Hodgkin lymphoma.

The FDA has expanded the prescribing information for axicabtagene ciloleucel to include prophylactic corticosteroids for all approved indications.

A supplemental biologics license application has been granted to trastuzumab deruxtecan-nxki for the treatment of adult patients with select HER2-positive breast cancer.

Recently presented findings demonstrate that aspacytarabine may represent a viable treatment option for various subsets of patients with acute myeloid leukemia.

Abatacept is now available for use in combination with certain immunosuppressants to prevent moderate to severe acute-graft-versus-host disease for select patients who have received unrelated donor hematopoietic stem cell transplant.

Pembrolizumab has been approved for the adjuvant treatment of adults and pediatric patients with stage IIB or IIC melanoma who have underwent complete resection.

In a phase 1 dose-escalation trial, treatment with the investigative agent was well tolerated with no dose-limiting toxicities.

Patients with neuroendocrine tumors across various origins experienced favorable responses after receiving tidutamab.

Ropeginterferon alfa-2b-njft is now an FDA-approved drug for the treatment of polycythemia vera.

After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.